1stOncology™: Cancer Intelligence Service – Page 15191 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Medtronic to Participate In Goldman Sachs Global Healthcare Conference

On May 29, 2018 Medtronic plc (NYSE:MDT), the global leader in medical technology, reported that it will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018, in Rancho Palos Verdes, Calif (Press release, Medtronic, MAY 29, 2018, View Source;p=RssLanding&cat=news&id=2351076 [SID1234527091]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Omar Ishrak, Medtronic chairman and chief executive officer, and Karen Parkhill, Medtronic executive vice president and chief financial officer, will answer questions about the company beginning at 8:00 a.m. PDT (10:00 a.m. CDT).

A live audio webcast of the session will be available on June 12, 2018, by clicking on the Investor Events link at View Source, and an archive of the session will be available on the same webpage later in the day.

Johnson & Johnson to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference

On May 29, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, at the Terranea Resort in Rancho Palos Verdes, California (Press release, Johnson & Johnson, MAY 29, 2018, View Source [SID1234527088]). Tom Cavanaugh, President, Oncology, Janssen Pharmaceuticals and Scott White, President, Immunology will represent the Company in a session scheduled at 9:20 a.m. (Pacific Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately two hours after the live webcast.

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

On May 29, 2018 Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center reported a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS) (Press release, Ipsen, MAY 29, 2018, View Source [SID1234527087]).

MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.

Alexandre Lebeaut, M.D., Executive Vice President, Research & Development and Chief Scientific Officer, Ipsen, commented, "We are very pleased to partner with the IACS at the MD Anderson Cancer Center whose reputation in scientific excellence and clinical care in Oncology is outstanding. Through this collaboration, we aim to synergize IACS’ scientific expertise with Ipsen’s drug development capabilities to deliver innovative therapies more rapidly to patients in need, and advance patient care in Oncology"

MD Anderson and Ipsen also will collaborate to conduct additional pre-clinical studies to further explore the potential of the drug candidate’s mode-of-action and expanded indications. The detailed financial terms of the agreement, including development and commercial milestones and royalties, have not been disclosed.

"We believe this partnership has the potential to deliver a new therapeutic option to our patients," said Stephen Hahn, M.D., chief medical executive at MD Anderson. "This focus on accelerating the development of efficient treatments is vital to our mission of ending cancer and to providing the very best care we can to those who need it most."

Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences

On May 29, 2018 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies reported it will participate in two upcoming investor conferences (Press release, Halozyme, MAY 29, 2018, View Source [SID1234527084]).

Dr. Helen Torley, president and chief executive officer will represent Halozyme in a question and answer session at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes on Tuesday, June 12 at 6:20 p.m. ET / 3:20 p.m. PT.

On Wednesday, June 20, Laurie Stelzer, senior vice president and chief financial officer will represent Halozyme in a question and answer session at the 2018 JMP Securities Life Sciences Conference in New York at 2:30 p.m. ET / 11:30 a.m. PT.

Webcasts of both sessions can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

Genmab to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

On May 29, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, California at 4:00 PM PDT on June 12, 2018 (1:00 AM CEST on June 13, 2018) (Press release, Genmab, MAY 29, 2018, View Source [SID1234527080]). A webcast of the presentation will be available on Genmab’s website at View Source